Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
|Articles|April 1, 2003
Genetic Links
Bal Harbour, Fla. - Genetic updates on neurofibromatosis and tuberous sclerosis and Langerhans cell histiocytosis presentation in the neonatal period were among the topics discussed by Lawrence F. Eichenfield, M.D., clinical professor of pediatrics and medicine (dermatology), University of California, San Diego, at the annual meeting of the Masters of Pediatrics, hosted by the University of Miami School of Medicine.
Advertisement
Advertisement
Related to this article
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Oral PKM2 Modulator Shows Early Efficacy in Atopic Dermatitis
2
Alopecia Areata Is a Medical Disease: Treatment Options and Defining Severity
3
Galderma to Acquire ZO Skin Health for $1.5 Billion
4
Chronic Hand Eczema Linked to Lost Productivity and Lower Quality of Life
5